Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24;30(13):2720.
doi: 10.3390/molecules30132720.

Anti-Amyloid Aggregation Effects of Gobaishi (Galla chinensis) and Its Active Constituents

Affiliations

Anti-Amyloid Aggregation Effects of Gobaishi (Galla chinensis) and Its Active Constituents

Sharmin Akter et al. Molecules. .

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that leads to memory loss and changes in mental and behavioral functions in elderly individuals. A major pathological feature of AD is the aggregation of amyloid-beta (Aβ) peptides, along with oxidative stress, inducing neurocellular apoptosis in the brain. Gobaishi (Galla chinensis), a traditional herbal medicine, has gained considerable attention for its constituents and potent therapeutic properties, particularly its strong inhibitory activity against Aβ fibril formation. In this study, we investigated the anti-Aβ aggregation effects of Gobaishi and its active constituents. We isolated two compounds by employing Thioflavin T (ThT) assay-guided fractionation, which were identified through various spectroscopic methods as pentagalloyl glucose (PGG) and methyl gallate (MG). Evaluation of their anti-Aβ aggregation effects revealed that PGG and MG contribute 1.5% and 0.7% of the activity of Gobaishi, respectively. In addition, PGG demonstrated significantly stronger DPPH radical scavenging activity (EC50 = 1.16 µM) compared to MG (EC50 = 6.44 µM). At a concentration of 30 µM, PGG significantly reduced the Aβ-induced cytotoxicity in SH-SY5Y cell lines compared to MG. Based on these findings, both Gobaishi and its active compound PGG are proposed as promising candidates for further investigation as potent anti-amyloidogenic agents in AD management.

Keywords: Gobaishi; amyloid-beta; antioxidant; methyl gallate; pentagalloyl glucose.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Metabolite profiling of Gobaishi using full scan mode covering negative (sid = 5) ion detection. (a) Total ion chromatogram of the EtOH fraction of Gobaishi. (b) Mass spectrum of the EtOH fraction of Gobaishi.
Figure 2
Figure 2
Isolation of Aβ aggregation inhibitor derived from Gobaishi.
Figure 3
Figure 3
Structure of (a) compound 1 (PGG) and (b) compound 2 (MG).
Figure 4
Figure 4
Inhibition of Aβ42 aggregation by pentagalloyl glucose (a) and methyl gallate (b). The data represent inhibitory activity as % of Aβ aggregation and are expressed as the mean ± SD; n = 3.
Figure 5
Figure 5
PGG inhibits Aβ aggregation as assessed by a turbidity assay. The legends are obtained from the Abs of (PGG + Aβ)−PGG. Data are presented as the mean ± SD of Abs of three independent experiments (n = 3). The asterisk (*) indicates a statistically significant difference compared to the Aβ alone group (one-tailed Student′s t-test, * p < 0.05).
Figure 6
Figure 6
Effect of RA (a), Gobaishi extract (b), PGG (c), and MG (d) on SH-SY5Y cells in the presence or absence of 30 μM Aβ at different concentrations. Results represent the mean  ±  SD (n  =  3). Differences between groups (Aβ vs. treatments) were evaluated for statistical significance using two-tailed Student′s t-test. * p  <  0.05, ** p  <  0.005, *** p  <  0.0005. ns stands for not significant.

Similar articles

References

    1. Khoba K., Kumar S., Chatterjee S., Purty R.S. Isolation, characterization, and in silico interaction studies of bioactive compounds from Caesalpinia bonducella with target proteins involved in alzheimer′s disease. Appl. Biochem. Biotechnol. 2023;195:2216–2234. doi: 10.1007/s12010-022-03937-1. - DOI - PubMed
    1. 2024 Alzheimer′s disease facts and figures. Alzheimer′s Dementia. 2024;20:3708–3821. doi: 10.1002/alz.13809. - DOI - PMC - PubMed
    1. World Health Organization Dementia. [(accessed on 17 October 2024)]. Available online: https://www.who.int/news-room/fact-sheets/detail/dementia.
    1. Trejo-Lopez J.A., Yachnis A.T., Prokop S. Neuropathology of Alzheimer′s disease. Neurotherapeutics. 2023;19:173–185. doi: 10.1007/s13311-021-01146-y. - DOI - PMC - PubMed
    1. Andrews S.J., Renton A.E., Fulton-Howard B., Podlesny-Drabiniok A., Marcora E., Goate A.M. The complex genetic architecture of Alzheimer′s disease: Novel insights and future directions. EBioMedicine. 2023;90:104511. doi: 10.1016/j.ebiom.2023.104511. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources